The immunoglobulin combination was separated and extracted from normal human plasma by the low-temperature ethanol method, and refined through further processing and virus inactivation steps. This product is a complete, unmodified natural lgG antibody with a purity of up to 98%. It contains no preservatives and antibiotics and is intended for intravenous infusion. Compared with intramuscular gamma globulin, it has a faster effect and a significant effect. advantage.
The global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) include Boya-Bio, Beijing Tiantan Biological Products, Hualan Bio, Guangdong Shuagnlin Bio-pharmacy, Weiguang Biological, Sinopharm, Shanghai RAAS, CTBB and Nanyue Biopharming, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19).
Report Scope
The Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Boya-Bio
Beijing Tiantan Biological Products
Hualan Bio
Guangdong Shuagnlin Bio-pharmacy
Weiguang Biological
Sinopharm
Shanghai RAAS
CTBB
Nanyue Biopharming
Segment by Type
1g/20ml
1.25g/25ml
2.5g/50ml
5g/100ml
10g/200ml
Segment by Application
Hospital
Clinic
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Overview
1.1 Product Overview and Scope of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)
1.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Type
1.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 1g/20ml
1.2.3 1.25g/25ml
1.2.4 2.5g/50ml
1.2.5 5g/100ml
1.2.6 10g/200ml
1.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Application
1.3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue 2019-2030
1.4.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales 2019-2030
1.4.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Competition by Manufacturers
2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Average Price by Manufacturers (2019-2024)
2.4 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19), Product Type & Application
2.7 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Competitive Situation and Trends
2.7.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Players 麻豆原创 Share by Revenue
2.7.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Retrospective 麻豆原创 Scenario by Region
3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region: 2019-2030
3.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region: 2019-2024
3.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region: 2025-2030
3.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region: 2019-2030
3.3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region: 2019-2024
3.3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region: 2025-2030
3.4 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Facts & Figures by Country
3.4.1 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2019-2030)
3.4.3 North America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Facts & Figures by Country
3.5.1 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2019-2030)
3.5.3 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2019-2030)
3.6.3 Asia Pacific Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2019-2030)
3.7.3 Latin America Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2019-2030)
4.1.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2019-2024)
4.1.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2025-2030)
4.1.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2019-2030)
4.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2019-2024)
4.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2025-2030)
4.2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2019-2030)
5.1.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2019-2024)
5.1.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2025-2030)
5.1.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2019-2030)
5.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2019-2024)
5.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2025-2030)
5.2.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Boya-Bio
6.1.1 Boya-Bio Corporation Information
6.1.2 Boya-Bio Description and Business Overview
6.1.3 Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
6.1.5 Boya-Bio Recent Developments/Updates
6.2 Beijing Tiantan Biological Products
6.2.1 Beijing Tiantan Biological Products Corporation Information
6.2.2 Beijing Tiantan Biological Products Description and Business Overview
6.2.3 Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
6.2.5 Beijing Tiantan Biological Products Recent Developments/Updates
6.3 Hualan Bio
6.3.1 Hualan Bio Corporation Information
6.3.2 Hualan Bio Description and Business Overview
6.3.3 Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
6.3.5 Hualan Bio Recent Developments/Updates
6.4 Guangdong Shuagnlin Bio-pharmacy
6.4.1 Guangdong Shuagnlin Bio-pharmacy Corporation Information
6.4.2 Guangdong Shuagnlin Bio-pharmacy Description and Business Overview
6.4.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
6.4.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments/Updates
6.5 Weiguang Biological
6.5.1 Weiguang Biological Corporation Information
6.5.2 Weiguang Biological Description and Business Overview
6.5.3 Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
6.5.5 Weiguang Biological Recent Developments/Updates
6.6 Sinopharm
6.6.1 Sinopharm Corporation Information
6.6.2 Sinopharm Description and Business Overview
6.6.3 Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
6.6.5 Sinopharm Recent Developments/Updates
6.7 Shanghai RAAS
6.6.1 Shanghai RAAS Corporation Information
6.6.2 Shanghai RAAS Description and Business Overview
6.6.3 Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
6.7.5 Shanghai RAAS Recent Developments/Updates
6.8 CTBB
6.8.1 CTBB Corporation Information
6.8.2 CTBB Description and Business Overview
6.8.3 CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
6.8.5 CTBB Recent Developments/Updates
6.9 Nanyue Biopharming
6.9.1 Nanyue Biopharming Corporation Information
6.9.2 Nanyue Biopharming Description and Business Overview
6.9.3 Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolio
6.9.5 Nanyue Biopharming Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Chain Analysis
7.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Production Mode & Process
7.4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales and 麻豆原创ing
7.4.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Channels
7.4.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Distributors
7.5 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Customers
8 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Dynamics
8.1 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Trends
8.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Drivers
8.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Challenges
8.4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Boya-Bio
Beijing Tiantan Biological Products
Hualan Bio
Guangdong Shuagnlin Bio-pharmacy
Weiguang Biological
Sinopharm
Shanghai RAAS
CTBB
Nanyue Biopharming
听
听
*If Applicable.